Abstract: The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of Clostridium chauvoei that represents the major cytotoxic activity of C. chauvoei. This toxin confers C. chauvoei its characteristic strong hemolytic activity towards erythrocytes of various species, since anti-CctA antibodies fully neutralize hemolysis by C. chauvoei on standard blood-agar medium or in cell-free supernatants of liquid cultures.

Abstract: The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of Clostridium chauvoei that represents the major cytotoxic activity of C. chauvoei. This toxin confers C. chauvoei its characteristic strong hemolytic activity towards erythrocytes of various species, since anti-CctA antibodies fully neutralize hemolysis by C. chauvoei on standard blood-agar medium or in cell-free supernatants of liquid cultures.

Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.

Abstract: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-?-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-?-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.

Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.

Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.

Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.

Abstract: A novel protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventative, and therapeutic techniques, including the preparation of traditional, recombinant, and improved bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.

Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.

Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.

Abstract: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-?-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-?-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.

Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AcxT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.

Abstract: A novel protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventative, and therapeutic techniques, including the preparation of traditional, recombinant, and improved bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.

Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.

Abstract: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-?-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-?-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.

Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AcxT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.

Abstract: A double rolling-lobe flexible member spring arrangement (2) includes two coaxial spring components (4a and 4b) which are arranged opposed to each other. The spring components essentially each include a rolling-lobe flexible member (6a and 6b) and respective roll-off pistons (8a and 8b). The two rolling-lobe flexible members (6 and 6b) define a common double rolling-lobe flexible member (6) and the two spring components (4a and 4b) have a common outer jacket (10). A reliable effective fixing of the flexible member (6) to the inner side of the outer jacket (10) is ensured. To provide this fixation, the double rolling-lobe flexible member (6) has a support ring (14) lying centrally on the inner side thereof and this support ring has a radial recess (16) on its periphery. The outer jacket (10) has a peripherally-extending raised portion at its inner periphery which engages into the recess (16) of the support ring (14) and defines a clamp contour.

Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.

Abstract: The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods for the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagnostic test for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strains and vaccine strains.

Abstract: The sleeve-shaped rolling-lobe flexible member (4) of a rolling-lobe spring (2) is made of elastomeric material and is provided with a reinforcement layer. The ends of the sleeve-shaped rolling-lobe flexible member (4) include neither beads nor cores. The rolling-lobe flexible member (4) is attached pressure-tightly to a cover (8) functioning as a connecting part and/or to a roll-off piston (10) of the spring (2). This pressure-tight attachment is achieved in that each clamping region (18, 20) of the connecting part (cover 8 and/or roll-off piston 10) is provided with a drawn-in connecting surface having at least one peripherally-extending raised portion (22, 24). Clamp rings (12, 14) are assigned to corresponding clamping regions (18, 20) of the connecting parts (8, 10). The clamp rings (12, 14) have respective peripherally-extending recesses (26, 28).